Parkinson's%20disease%20-and-%20parkinson's%20disease%20dementia News

News

Is loneliness a risk factor for Parkinson’s disease?

Natalia Reoutova, 20231010000000

A large population-based prospective cohort study finds that loneliness is associated with increased risk of incident Parkinson’s disease (PD) across demographic groups, independently of depression and other prominent risk factors, including genetic risk.

Nitrate derived from vegetables lowers risk of dementia

Stephen Padilla, 20230907120000

A higher intake of dietary nitrate from vegetables appears to reduce the risk of dementia in the general population, suggests a study.

Parkinson’s disease: More hours of good on-time with extended- vs immediate-release carbidopa-levodopa

Natalia Reoutova, 20230905000000

IPX203, a new oral extended-release (ER) carbidopa-levodopa (CD-LD) combination, provides more hours of good on-time per day than immediate-release (IR) CD-LD, according to results of a phase III clinical trial in patients with Parkinson’s disease (PD).

Brain stimulation helps with Parkinson's disease-related walking problems

Jairia Dela Cruz, 20230813160000

Delivering electrical stimulation over the cerebellum appears to improve gait disturbances in patients with Parkinson’s disease (PD) and help them walk better, as reported in a study from Japan.

Comorbid depression and sleep behaviour disorder puts patients and relatives at risk of neurodegeneration

Kanas Chan, 20230808023534

Comorbid major depressive disorder and rapid eye movement sleep behaviour disorder (MDD-RBD) is a common subtype of MDD. These patients and their first-degree relatives (FDRs) are at risk of neurodegeneration, researchers from the Chinese University of Hong Kong (CUHK) have reported.

Fixed-dose combo tackles PD symptoms while minimizing daytime sleepiness

Jairia Dela Cruz, 20230516140000

P2B001, an investigational drug formulation that combines extended release (ER) doses of pramipexole and rasagiline, shows promise in managing Parkinson’s Disease (PD), conferring symptom control similar to that achieved with the marketed ER pramipexole while reducing the troublesome side effect of excessive daytime sleepiness.

Gut dysbiosis evident in patients with prodromal PD and their first-degree relatives

Natalia Reoutova, 20230510000000

A cross-sectional study from the Chinese University of Hong Kong suggests that Parkinson’s disease (PD)–like gut dysbiosis occurs at preclinical prodromal stages of PD, in patients with video-polysomnography (v-PSG)–confirmed REM sleep behavior disorder (RBD) and even in their younger first-degree relatives (RBD-FDR).

Sugary drinks raise dementia risk

20230427130000

People who regularly consume sugar-sweetened (SSBs) and artificially sweetened beverages (ASBs) appear to be at greater risk of dementia, but those who drink natural juices (NJs) in moderation show a reduced risk, suggests a study.

Focused ultrasound ablation improves motor function in Parkinson’s

20230405180000

Patients with Parkinson’s disease (PD) who have undergone unilateral focused ultrasound ablation of the internal segment of globus pallidus show improved motor function or reduced dyskinesia over a period of 3 months, although the procedure comes with adverse events, according to a study.

Bean intake may lower dementia risk

20230220130000

Dietary consumption of beans appears protective against the risk of disabling dementia in patients without a history of stroke, results of the Circulatory Risk in Communities Study (CIRCS) have shown.

Breaking ground in migraine management: First Consensus Guidelines from the Headache Society of Singapore

06 Dec 2023

In a pioneering effort, the Headache Society of Singapore (HSS) has released the first edition of consensus guidelines focusing on the approach to headache disorders and management of migraine. Amid a rapidly growing array of therapeutic options, standardizing treatment approaches is crucial. These guidelines provide a pivotal resource for healthcare professionals navigating the complex landscape of headache disorders, with a special focus on migraine management in adults.

Long COVID: What we have learned so far

Prof. Ghassan Dbaibo, 27 Apr 2023

The WHO defines long COVID as a condition that occurs 3 months from COVID-19 onset, whose symptoms last ≥2 months and cannot be attributed to an alternative diagnosis. In an interview with MIMS Doctor, Professor Ghassan Dbaibo of the Center for Infectious Diseases, American University of Beirut, Beirut, Lebanon, describes the evolving attitudes towards long COVID among healthcare professionals (HCPs), some unexpected predisposing factors, potential biological mechanisms behind prolonged symptom duration and shares data on vaccination’s protective effects against long COVID.

New advancements in MRI technology for improved diagnostics and patient experience

12 Feb 2019

At a recent Philips sponsored dinner symposium, a panel of industry and clinical experts convened to present data on key advancements in magnetic resonance imaging (MRI) solutions, with focus on two new Philips solutions – Ingenia Elition and Ingenia Ambition.